Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2023-02-15 | Reverse | 1:15 |
electroCore, Inc. develops and commercializes non-invasive vagus nerve stimulation devices like gammaCore for treating migraines and cluster headaches.
A portable, non-invasive vagus nerve stimulator (nVNS) designed for military use to boost learning, mood, and cognitive performance.
electroCore reported record revenue for the second quarter of 2025, a 20% increase year-over-year to $7.4 million, which slightly beat analyst expectations. However, the company also reported a wider-than-expected earnings per share loss of -$0.35, missing analyst estimates and signaling to investors that the path to profitability may be longer than anticipated. The significant miss on earnings overshadowed the revenue growth and led to a sharp decline in the company's stock price.
electroCore completed its acquisition of NeuroMetrix, bringing the Quell wearable neuromodulation platform into its portfolio. This move strategically expands the company's focus beyond its core non-invasive vagus nerve stimulation (nVNS) technology and into the broader chronic pain market, specifically targeting fibromyalgia.
electroCore (NASDAQ: ECOR - Get Free Report) and Enovis (NYSE: ENOV - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk. Analyst Ratings This is a breakdown of current recommendations
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
 PYPD | $4.94 | COMPARE |
 RNXT | $1.33 | COMPARE |
 MYO | $1.39 | COMPARE |
 HYPD | $3.28 | COMPARE |
 YI | $3.09 | COMPARE |
 NMTC | $1.08 | COMPARE |
 RBOT | $0.05 | COMPARE |
